Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BioMarin Pharmaceutical : Amendment to Credit Agreement (Form 8-K)

06/02/2021 | 06:05am EDT

Amendment to Credit Agreement

On May 28, 2021, BioMarin Pharmaceutical Inc., a Delaware corporation (the 'Company'), entered into an Amendment Agreement (the 'Amendment') in respect of its Credit Agreement, dated as of October 19, 2018, (as amended, the 'Credit Agreement') with the Guarantor (as defined below), Bank of America, N.A., a national banking association, as Administrative Agent and Swing Line Lender ('Bank of America' or the 'Administrative Agent'), Citibank, N.A. as L/C Issuer, and the Lenders party thereto (the 'Lenders'), to, among other things, extend the maturity date of the Revolving Credit Facility (as defined below) to May 28, 2024.

The Credit Agreement provides for up to $200 million in revolving loans (the 'Revolving Credit Facility'), none of which was drawn at closing. Subject to the satisfaction of certain conditions precedent, the Company is entitled to draw funds at its discretion until the Revolving Credit Facility matures on May 28, 2024, extended from October 18, 2021, as part of the Amendment, at which time all outstanding amounts become due and payable (except that if at least $100 million aggregate principal amount of the Company's 0.599% senior subordinated convertible notes due in 2024 and the Company's 1.25% senior subordinated convertible notes due in 2027 remain outstanding on March 14, 2024 and certain other conditions have not been met, the Company may be required to repay all amounts borrowed under the Credit Agreement on March 14, 2024). The Company expects to use the proceeds of the Revolving Credit Facility to finance ongoing working capital needs (including, but not limited to, timing differences resulting from the strategic management of short-term investments) and for other general corporate purposes. The Company paid a facility fee to the Lenders in connection with the Amendment.

Loans under the Revolving Credit Facility will continue to bear interest at a floating rate of interest per annum based either on, at Company's option, (a) the London Interbank Offered Rate ('LIBOR') (except that if LIBOR is less than zero it shall be deemed to be zero for purposes of the Credit Agreement), or a LIBOR successor rate, plus an applicable margin or (b) the Base Rate, generally the prime lending rate, plus an applicable margin. The applicable margin will continue to be based upon the Company's net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods. The Amendment lowers the applicable margin range (a) in respect of LIBOR rate loans from 1.20% to 1.95% per annum to 1.00% to 1.75% per annum and (b) in respect of Base Rate loans from 0.20% to 0.95% per annum to 0.00% to 0.75% per annum. The Amendment lowers the Commitment fees payable on the undrawn amount from a range of 0.20% to 0.35% per annum to a range of 0.15% to 0.30% per annum, in each case based upon the Company's net leverage ratio and EBITDA for each of the two most recently ended four-quarter measurement periods.

The Company's obligations under the Credit Agreement are guaranteed by its direct subsidiary, California Corporate Center Acquisition LLC (the 'Guarantor'), and such obligations may in the future be guaranteed by certain other material domestic subsidiaries of the Company.

The Company has the right, but not the obligation, to prepay the Revolving Credit Facility in whole or in part and/or terminate the Revolving Credit Facility without premium or penalty at any time.

The Credit Agreement includes customary representations, warranties and covenants by the Company and certain of its subsidiaries, including, among other things, restrictions on the Company's and such subsidiaries' ability to incur additional indebtedness, dispose of its assets, incur liens, make investments, and pay dividends or other distributions, in each case subject to specified exceptions. The Credit Agreement also contains customary indemnification obligations and customary events of default, including, but not limited to, failure to timely make payments when due under the Credit Agreement, failure to comply with any of the covenants under the Credit Agreement or any other loan document, the occurrence of certain insolvency or bankruptcy-related events, cross-default to certain other material indebtedness and the occurrence of a 'change of control' (as defined in the Credit Agreement).

During the occurrence and continuance of an event of default by the Company under the Credit Agreement, the Lenders would be entitled to exercise their remedies thereunder, including termination of the commitment of each Lender to make loans and any obligation of the issuer of letters of credit under the Revolving Credit Facility to make credit extensions, and the right to accelerate any outstanding obligations under the Credit Agreement.

The foregoing description of the Credit Agreement is not intended to be complete and is qualified in its entirety by reference to the full text of the Credit Agreement, which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Qfor the fiscal quarter ended June 30, 2021.

Creation of a Direct Financial Obligation or an Obligation under an Off-BalanceSheet Arrangement of a Registrant.

The information contained in Item 1.01 above is incorporated herein by reference.


BioMarin Pharmaceutical Inc. published this content on 02 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 02 June 2021 10:04:06 UTC.

ę Publicnow 2021
07/22BIOMARIN PHARMACEUTICAL : Announces Oral Presentation at International Society
07/21BIOMARIN PHARMACEUTICAL : Pharma's Gene Therapy Candidate Shows Bleed Control Ov..
07/21BIOMARIN PHARMACEUTICAL : Announces Oral Presentation at International Society o..
07/20BIOMARIN PHARMACEUTICAL : Announces Oral Presentation of Positive One-Year Resul..
07/19BIOMARIN PHARMACEUTICAL : Announces Oral Presentation of Positive One-Year Resul..
07/19BioMarin Announces Oral Presentation of Positive One-Year Results from Phase ..
07/15BIOMARIN PHARMACEUTICAL : European Regulator Accepts BioMarin's Marketing Applic..
07/15BIOMARIN PHARMACEUTICAL : European Medicines Agency Validates BioMarin's Marketi..
07/15European Medicines Agency Validates Biomarin's Marketing Authorization Applic..
More news
Financials (USD)
Sales 2021 1 822 M - -
Net income 2021 -99,0 M - -
Net cash 2021 183 M - -
P/E ratio 2021 -147x
Yield 2021 -
Capitalization 14 135 M 14 135 M -
EV / Sales 2021 7,66x
EV / Sales 2022 6,22x
Nbr of Employees 3 059
Free-Float 99,4%
Duration : Period :
BioMarin Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOMARIN PHARMACEUTICAL INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 77,35 $
Average target price 107,86 $
Spread / Average Target 39,4%
EPS Revisions
Managers and Directors
Jean-Jacques BienaimÚ Chairman & Chief Executive Officer
Brian R. Mueller Chief Financial Officer & Executive Vice President
Henry J. Fuchs President-Worldwide Research & Development
Eduardo E. Von Pervieux Chief Information Officer
Geoffrey M. Nichol Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
CSL LIMITED3.15%98 398
BIOGEN INC.32.89%49 469